Compare TOVX & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOVX | HCWB |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 14.8M |
| IPO Year | 2012 | 2021 |
| Metric | TOVX | HCWB |
|---|---|---|
| Price | $0.26 | $1.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 11.3M | 2.6M |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.07 | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.25 |
| 52 Week High | $0.86 | $7.35 |
| Indicator | TOVX | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 43.71 |
| Support Level | $0.18 | $1.03 |
| Resistance Level | $0.28 | $1.26 |
| Average True Range (ATR) | 0.03 | 0.19 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 13.38 | 4.53 |
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.